Pharmaceutical

CVS Health enters biosimilar fray with launch of new subsidiary

The newly-launched business, called Corvardis, is already targeting the Humira biosimilar landscape with Hyrimoz via a planned Sandoz-partnered launch in Q1 2024.

Aug 24, 2023 - 20:00
CVS Health enters biosimilar fray with launch of new subsidiary
The newly-launched business, called Corvardis, is already targeting the Humira biosimilar landscape with Hyrimoz via a planned Sandoz-partnered launch in Q1 2024.
Read the original article

Tags:

Previous Article

How the first Native Hawaiian psychiatrist set a course for diversifying medicine

Next Article

US Elections: Vivek Ramaswamy makes brazen debate debut

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Verve Therapeutics and Lilly partner to advance gene editing programme

Verve Therapeutics and Lilly partner to advance gene ed...

Jun 15, 2023

Ipsen outlines $461m for ex-US rights to Day One’s glioma therapy

Ipsen outlines $461m for ex-US rights to Day One’s glio...

Jul 26, 2024

NICE expands access of Paxlovid to further 1.4 million Covid-19 patients

NICE expands access of Paxlovid to further 1.4 million ...

Jan 11, 2024